Patents Examined by Lianko G Garyu
  • Patent number: 10376532
    Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor, and optionally bivalirudin. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: August 13, 2019
    Assignee: Chiesi Farmaceutici, S.p.A.
    Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
  • Patent number: 10376561
    Abstract: Toll-like receptor 4 (TLR4), the innate immunity receptor for bacterial endotoxins, plays a pivotal role in the induction of inflammatory responses. There is a need to develop molecules that block either activation through TLR4 or the downstream signaling pathways to inhibit the storm of inflammation typically elicited by bacterial lipopolysaccharide (LPS), which is a major cause of the high mortality associated with bacterial sepsis. The present invention provides that a single intraperitoneal injection of 15 ?g Fasciola hepatica fatty acid binding protein (Fh12) 1 hour before exposure to LPS suppressed significantly the expression of serum inflammatory cytokines in a model of septic shock using C57BL/6 mice. Whereas Fh12 alone did not induce cytokine expression, it significantly suppressed the expression of IL12, TNF?, IL6 and IL1? cytokines as well as iNOS2 in bmM?s, and also impaired the phagocytic capacity of bmM?s.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: August 13, 2019
    Assignee: University of Puerto Rico
    Inventors: Ana M. Espino, Ivelisse Martin
  • Patent number: 10363323
    Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of labels to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the label(s) to be specifically delivered to the liver. The present invention furthermore relates to the diagnostic use of the inventive hydrophobic modified peptides as well as to a method for the diagnosis of liver diseases or disorders.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: July 30, 2019
    Assignee: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn, Thomas Müller, Vasileios Askoxylakis
  • Patent number: 10363284
    Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-DPro7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Xaa13-Xaa14-Xaa15-Pro16-), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa3, Xaa6, Xaa8, Xaa13, Xaa14 and Xaa15 being amino acid residues of certain types which are defined in the description and the claims, have favorable pharmacological properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: July 30, 2019
    Assignee: POLYPHOR AG
    Inventors: Frank Otto Gombert, Daniel Obrecht, Alexander Lederer, Johann Zimmermann, Christian Oefner
  • Patent number: 10357535
    Abstract: Lyophilized daptomycin formulations having improved reconstitution times are provided. The lyophilized daptomycin formulations include an additive, which can be a pharmaceutically acceptable antioxidant, a pharmaceutically acceptable organic acid or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable glucose derivative or a pharmaceutically acceptable salt thereof, or a combination thereof. Also provided are methods of methods of preparing the lyophilized daptomycin formulations, and methods of treating bacterial infections and treating or preventing biofilms by using the lyophilized daptomycin formulations.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: July 23, 2019
    Assignee: Hospira Australia Pty Ltd
    Inventors: Jim Alexiou, Andrew Malcolm Knill, Noel Norris, Darryl Whittaker
  • Patent number: 10357533
    Abstract: The proposed drug relates to medicine and veterinary applications, in particular, as a means for effective control of acute and/or chronic pain, and may be used in emergency medicine for the treatment of acute and/or chronic pain, including the late stages of cancer. The stated means is based on a compound for preventing and/or treating acute or chronic pain in a subject, including an analgesic peptide having an amino acid sequence H-Tyr-D-Arg-Phe-Gly-NH2 or an amino acid sequence H-Tyr-D-Arg-Phe-Sar-OH. Also, a method of use/administration of the compound for the prevention and/or treatment of acute and/or chronic pain is disclosed.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 23, 2019
    Assignee: PVP LaBs PTE, Ltd.
    Inventors: Vyacheslav Stanislavovich Kosorukov, Evgeny Stanislavovic Rzhaninov, Nikolai Vasilievich Korobov
  • Patent number: 10358670
    Abstract: A method for the production of nucleic acid encoding a target protein. The method comprises (a) providing an array of RNA or DNA molecules including one or more encoding the target protein; (b) generating a target protein from the array to form RNA-protein or DNA-protein complexes in which the RNA or DNA molecule is non-covalently or covalently bound to the complex; (c) separating the complexes into compartments wherein most or all of the compartments contain no more than one complex; (d) subjecting the complexes to reaction conditions which allow target protein activity; and (e) selecting nucleic acid encoding the target protein on the basis of the activity associated therewith, wherein when the complex is a DNA-protein complex in which the DNA is non-covalently bound, step b) is performed in the absence of separate compartments for each complex.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: July 23, 2019
    Assignee: THERMO FISHER SCIENTIFIC BALTICS UAB
    Inventors: Arvydas Janulaitis, Remigijus Skirgaila, Dangira Siksniene
  • Patent number: 10358465
    Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: July 23, 2019
    Assignees: Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center, University of Rochester
    Inventors: Alan J. Waring, Frans J. Walther, Larry M. Gordon, Robert H. Notter
  • Patent number: 10351600
    Abstract: A peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: July 16, 2019
    Assignees: National Cerebral and Cardiovascular Center, JMS Co., Ltd.
    Inventors: Tetsuji Yamaoka, Sachiro Kakinoki, Shunsuke Baba, Yoshiya Hashimoto
  • Patent number: 10351618
    Abstract: The present invention provides UTI fusion proteins, DNA sequences for producing the same, and pharmaceutical compositions and methods of using the same.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: July 16, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Aaron Chamberlain, Qiang Liu, Mathias Schmidt
  • Patent number: 10336789
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Grant
    Filed: October 29, 2017
    Date of Patent: July 2, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Moshe Oren, Varda Rotter, Perry Tal
  • Patent number: 10330687
    Abstract: The invention provides populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens. The peptide populations comprise peptides derived from immunogenic fragments of the Anaplasma Outer Membrane Protein proteins. The invention also provides devices, methods, and kits comprising the populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens and the diagnosis of anaplasmosis. Methods of identifying the particular Anaplasma species infecting a subject using the peptide populations of the invention are also disclosed.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: June 25, 2019
    Assignee: ABAXIS, INC.
    Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile, Andrew P. Rogers, Timothy P. Forsyth, Jeremy D. Walker, Cristina R. Cuesico
  • Patent number: 10293024
    Abstract: A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7 or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which from 1 to 5 amino acids have been altered, wherein the compound binds to MAP kinase p38?. The compounds are useful in binding to and inhibiting MAP kinase p38?, and are useful as research tools, in drug discovery, medicine, particularly for treating inflammatory conditions.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: May 21, 2019
    Assignee: Blueberry Therapeutics Limited
    Inventor: John Ridden
  • Patent number: 10286047
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 14, 2019
    Assignees: CSL Behring GmbH, Universität Bern
    Inventors: Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
  • Patent number: 10287614
    Abstract: A method for the production of nucleic acid encoding a target protein. The method comprises (a) providing an array of RNA or DNA molecules including one or more encoding the target protein; (b) generating a target protein from the array to form RNA-protein or DNA-protein complexes in which the RNA or DNA molecule is non-covalently or covalently bound to the complex; (c) separating the complexes into compartments wherein most or all of the compartments contain no more than one complex; (d) subjecting the complexes to reaction conditions which allow target protein activity; and (e) selecting nucleic acid encoding the target protein on the basis of the activity associated therewith, wherein when the complex is a DNA-protein complex in which the DNA is non-covalently bound, step b) is performed in the absence of separate compartments for each complex.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: May 14, 2019
    Assignee: THERMO FISHER SCIENTIFIC BALTICS UAB
    Inventors: Arvydas Janulaitis, Remigijus Skirgaila, Dangira Siksniene
  • Patent number: 10287339
    Abstract: Hydrolyzed collagen types I, II, and V powder compositions, method of preparing the compositions, and use of the compositions in treating a variety of ailments. The compositions are topically or orally administered to an individual at a daily dosage between 1500 mg and 2000 mg.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: May 14, 2019
    Inventor: Ahmad Alkayali
  • Patent number: 10287319
    Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: May 14, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • Patent number: 10258588
    Abstract: The present invention is directed to compositions comprising physiologically acceptable, metabolic lipids, and physiologically acceptable, preferably biodegradable controlled release (CR) compounds, wherein the lipids are cell-free and the CR compounds release the metabolic lipids over a delayed time period under physiological conditions. In addition, the present invention relates to the use of such a composition for producing a cosmetic or therapeutic composition, preferably for fat tissue expansion or fat tissue repair. Also, the invention pertains to a method for the therapeutic or cosmetic treatment of a mammal comprising the administration of the composition of the invention and preferably injecting the composition while withdrawing the injection needle until the tissue area of interest is treated.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: April 16, 2019
    Assignee: PB&B SA
    Inventors: Anthony Youri Aho, Raghunathan Sandeep
  • Patent number: 10253213
    Abstract: The present invention relates to a method for coating an inert or naturally occurring material with a silk polypeptide. It further relates to a coated inert or naturally occurring material obtainable by said method and to uses thereof. It also relates to products comprising said coated material.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: April 9, 2019
    Assignee: Amsilk GmbH
    Inventors: Axel H. Leimer, Lin Romer
  • Patent number: 10246641
    Abstract: The present invention relates to processes for producing industrial products such as hydrocarbon products from non-polar lipids in a vegetative plant part. Preferred industrial products include alkyl esters which may be blended with petroleum based fuels.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: April 2, 2019
    Assignee: THE COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: Thomas Vanhercke, James Robertson Petrie, Anna El Tahchy, Surinder Singh, Qing Liu